Bristol-Myers Squibb (BMY) said Monday that its drug Breyanzi achieved "high, lasting response rates" among patients with relapsed or refractory marginal zone lymphoma in a phase 2 study.
The company said 95.5% of 66 evaluable patients showed an overall response, while 62.1% showed a complete response.
At 24 months, 88.6% sustained a response, 85.7% achieved progression-free survival, and 90.4% showed overall survival, the company said.
Median survival for patients with marginal zone lymphoma with multiple relapses is 3 to 5 years, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。